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excelent safety record. In this paper we explored the pos-
sible protective role of lubricant eye drops on ocular sur-
face in patients using topical antiglaucomatous therapy. 
We also explored if there is a difference in protection of 
lubricants regarding the preservative in the lubricant it-
self. We compaired the changes on precorneal tear ﬁ lm 
stability in patients using lubricants with preservaives 
that are representatives of two main preservative groups.
Methods
This was a prospective study. From Glaucoma cabinet 
in Department of Ophthalmology of General Hospital Za-
dar we recruited patients with primary open angle glau-
coma. There were total of 60 patients, 28 male (46%) and 
32 female (54%) age 45–70 years (median 54.5y) using 
topical antiglaucomatous therapy with BAK preservative 
and good regulation of intraocular pressure. They used 
therapy for 2–5 years and they had no objections or side 
effects of the therapy. We devided patients into 2 groups 
of 30 patients. Groups were uniformed in manner that in 
each group there were 6 patients on latanoprost therapy, 
5 patients were using timolol dorsolamide ﬁ xed combina-
tion, 4 patients were using travoprost and 4 patients used 
Glaucoma is a cronic disease, life long, and its therapy 
is long termed aswell. To be effective it has to be used in 
regular and continuous manner. Topical antiglaucoma-
tous therapy is often associated with simptoms and signs 
of toxicity, inﬂ amatory changes of the ocular surface and 
dicrease of tear ﬁ lm break up time (TBUT). TBUT test is 
test for evaluating precorneal tear ﬁ lm stability. Patients 
with dry eye and ocular surface disorders can be evalu-
ated by TBUT mesuring. The main causative factor for the 
toxicity and ocular surface disorders can be the preserva-
tive or an active compound of the drug. Preservative is an 
aditive to the drug with two main purposes – it acts 
against decay, discoloration and spoilage and it has a role 
in destroying or inhibiting multiplication of microorgan-
isms. There are two main groups of preservatives, deter-
gent and oxidative. Detergent preservatives can cause cell 
membrane lysis and acumulate in ocular tisue. They have 
dose dependent effect. They also interfere with the integ-
rity of superﬁ cial lipid layer of the tear ﬁ lm, reduce the 
TBUT and may contribute to the ocular surface disease.. 
BAK as the most often used preservative in ophthalmic 
solutions is the detergent preservative. Second group are 
oxidative preservatives with Stabilised Oxochloro Com-
plex (SOC) as the main representative. Their key compo-
nent is sodium chloride and it has mild cytotoxic effect and 
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A B S T R A C T
Topical glaucoma therapy is a long termed, usually lifelong. Antiglaucomatous drugs have toxic effects on ocular 
surface, due to preservative toxicitiy or the drug itself. Adding a lubricant eyedrops to antiglaucomatous therapy, espe-
cially if considering the preservative used, can have protective effect. The purpose of this study was to evaluate the stabil-
ity of precorneal tear ﬁ lm in glaucoma patient prior and after administration of lubricant eye drops with different tipe of 
preservatives. The study showed the protective role of ocular surface lubrication especially when using drugs with less 
harmful preservatives.
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servative and the other with SOC preservative aditional 
to their topical antiglaucomatous therapy. They used lu-
bricants twice a day in the same regimen in both groups. 
We reevaluated tear ﬁ lm quality 3 months after the lubri-
cant drops adminstration measuring TBUT. For statisti-
cal data analysis we used t-test.
Results
Baseline TBUT values in ﬁ rst group of patients were 
3–14 sec. Three months after using lubricant with BAK 
preservative we measured the following values changes: 
in 9 examinees values were unchanged- the same as base-
line, in one examenee TBUT was 1 sec less than baseline. 
In 20 examenees TBUT values three months after lubri-
cant drops adminitration were higher, in 5 examinees for 
2 sec, and in the 15 examenees for 1 sec (Figure 2). The 
change in TBUT between 1st and 2nd test was statistically 
signifﬁ cant (p<0.05). In second group of examenees that 
used SOC lubricant eyedrops, baseline values of TBUT 
were 4–14 sec. Three month later values remained the 
same in 9 patients and in one patient TBUT was less than 
the baseline. In the remaining 20 patients values were 
higher than the baseline, in 8 examenees for 1 sec, in 8 for 
2 sec, in one for 3 sec. In two examenees values were 4 sec 
higher and in 1 for 5 sec (Figure 3). The change in TBUT 
between 1st and 2nd test was statistically signifﬁ cant 
(p<0.05). Comparing the groups, baseline TBUT (1st test) 
values were not statistically different (p>0.05) and the 
change in TBUT (2nd test) between the groups was not 
statistically signiﬁ cant (p>0.05).
Discussion and Conclusion
Long term usage of antiglaucomatous therapy can have 
toxic effect on ocular surface. There are clinical evidence 
that the number of medications, their prolonged use and 
total BAK exposure are risc factors to develop ocular sur-
face disease in patients with glaucoma1.BAK appears  to 
be the main contributor to corneal toxicity in a dose – de-
pendent manner2.There are re ports examinating ocular 
surface using recently developed confocal cornea micros-
copy that showed signiﬁ cantly reduced tear production 
and TBUT reduction, and also changes in corneal epithe-
lial cells and Langerhans cell densities in patients using 
topical antiglaucoma therapy3,4. TBUT test evaluets the 
stability of the precorneal tear ﬁ lm, and in diferent stud-
ies comparing signs, simptoms and predictive tools for dry 
eye disease and ocular surface disorders it is shown to be 
the most reliable test combined with vital staining5. There 
are r eported studies comparing using of antiglaucoma 
topical drugs with preservative and preservative free 
drug, and they mostly report improved quality of life and 
and less dry eye simptoms when less preservatives used6,7. 
There are aims in modern glaucoma therapy to optimise 
the concentration of BAK or to use preservative free drugs 
in order to improve condition of the ocular surface8. Ocular 
surf ace disease impacts the glaucoma treatment outcome 
and it can result in noncomplience, lack of adherence and 
Fig. 1. Examinees according to therapy.
Fig. 2. Tear ﬁ lm break-up time (TBUT) test – BAK group. Test 
1 – TBUT measures at baseline. Test 2 – TBUT measures 3 
months after lubricant administration.
Fig. 3. Tear ﬁ lm break-up time (TBUT) test – SOC group. Test 1 
– TBUT measures at baseline. Test 2 – TBUT measures 3 
months after lubricant administration.
timolol. Two patients in each group used latanoprost and 
timolol dorsolamid ﬁ xed combination, travoprost and timo-
lol dorsolamid, two patients used travoprost and brinzola-
mid and two patients used betaxolol (Figure 1). In both 
groups we evaluated tear ﬁ lm quality on slit lamp exami-
nation by measuring tear ﬁ lm break up time (TBUT) at 
baseline. After baseline evaluation we administrated all 
the patients lubricant eye drops, each group with different 
preservative. One group used lubricants with BAK pre-
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eventually visual impairment9. In some est imations about 
20% of patients on topical glaucoma or ocular hyperten-
sion treatment may need preservative free medications10.
Therefore simptoms and signs of ocular surface disease 
should not be overlooked, and glaucoma treatment should 
be adapted by avoiding polytherapy- especially considering 
the number of drops per day, concentration and tipe of 
preservative used. In that manner we can improve com-
plience and adherence to therapy and ﬁ nal outcome of 
glaucoma therapy. In this study we premised the protec-
tive effect of lubricant eye drops on ocular surface in gen-
eral and especially if less harmfull preservative used. Our 
results showed increased tear ﬁ lm stability measured 
with TBUT test that was statistically signifﬁ cant in both 
groups of patients, using lubricant with BAK and SOC 
preservative. There was no statistically signiﬁ cant differ-
ence between BAK and SOC group in the investigated 
period of time. There are other studies investigating this 
protective role and they also concluded that lubricant eye 
drops restore hyperosmolarity and stimulate tear produc-
tion11. To avoid o r at least minimise the chance for ocular 
surface disease an ophthalmologist should consider avoid-
ing polytherapy, choose preparations with less concentra-
tions of preservatives and less harmful preservatives. Also 
adding lubricant eye drops in an therapy option. In our 
study the protective role of lubricats was proved for lubri-
cants in general and with no difference regarding the pre-
servative used in lubricant itself.
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PROMJENE POVRŠINE OKA GLAUKOMSKIH BOLESNIKA POVEZANE SA TOPIČKOM TERAPIJOM
S A Ž E T A K
Topička terapija glaukoma je dugotrajna, obično i doživotna. Antiglaukomski lijekovi imaju toksični učinak na 
površinu oka, dijelom radi utjecaja konzervansa dijelom radi same aktivne komponente lijeka. Uvođenje u tearpiju kapi 
za lubrikaciju može imati protektivni učinak na površinu oka, pogotovo ako se vodi računa o konzervansu u lubrikantu. 
Cilj ove studije bio je evaluirati stabilnost prekornealnog suznog ﬁ lma u pacijenata sa glaukomom prije i nakon uvođenja 
lubricirajućih kapi sa različitim vrstama konzervansa. Studija je pokazala protektivnu ulogu lubrikanata na površinu 
oka, naročito kod korištenja manje štetnih konzervansa.
